drugset / Trial / NCT06847607
A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of ipecopam in the treatment of refractory/relapsed AIHA.
Timeline
- Start
- 2025-03-01
- Primary completion
- 2025-10-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iptacopan | Small molecule | — | — |